Université de Reims Champagne-Ardenne, SFR CAP-Santé (FED 4231), Laboratoire de Biochimie Médicale et Biologie Moléculaire, 51100 Reims, France.
CNRS UMR 7369, Matrice Extracellulaire et Dynamique Cellulaire - MEDyC, 51100 Reims, France.
Pharmacogenomics. 2020 Jul;21(10):705-720. doi: 10.2217/pgs-2020-0021. Epub 2020 Jun 22.
Immunotherapies are now considered as a pillar of non-small-cell lung cancer treatment. The main targets of immune-checkpoint inhibitors (ICI) are programmed cell death 1/programmed cell death ligand 1 and cytotoxic T-lymphocyte antigen 4, aiming at restoring antitumor immunity. Despite durable responses observed in some patients, all patients do not benefit from the treatment and almost all responders ultimately relapse after some time. In this review, we discuss the biomarkers that could be used to predict response to ICI, the current indications of ICI in non-small-cell lung cancer, the mechanisms inducing tumor-cell intrinsic or extrinsic resistance to ICI and finally, the potential treatment response monitoring.
免疫疗法现已被视为非小细胞肺癌治疗的重要手段之一。免疫检查点抑制剂（ICI）的主要靶点是程序性细胞死亡蛋白 1/程序性细胞死亡配体 1 和细胞毒性 T 淋巴细胞相关抗原 4，旨在恢复抗肿瘤免疫。尽管一些患者观察到了持久的反应，但并非所有患者都能从治疗中获益，几乎所有的应答者在一段时间后最终都会复发。在这篇综述中，我们讨论了可用于预测对 ICI 反应的生物标志物、ICI 在非小细胞肺癌中的现有适应证、导致肿瘤细胞内在或外在对 ICI 耐药的机制，以及最后潜在的治疗反应监测。
